Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs ResMed Inc. — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B), while ResMed Inc. trades at $230.96 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 22× YieldMax NVDA Option Income Strategy ETF's market cap, and ResMed Inc. pays a 1.16% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| NVDY | RMD | |
|---|---|---|
Market Cap | $1.45B | $31.89B |
Volume | 1,943,739 | 618,314 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $277.88 |
52-Week Low | $11.58 | $182.82 |
Typical Hold Time | — | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.64, down 2.84% on the day amid a bearish technical signal. The fund generates income through options on NVIDIA stock but faces headwinds from declining volatility, which caps upside participation and has led to recent analyst downgrades. Weekly dividend distributions continue, but concerns over net asset value erosion persist.
The outlook for NVDY is cautious, as its high distribution yield comes with structural limitations on capital appreciation. Investment opportunity lies in income generation for risk-tolerant investors, but risks include NAV erosion and dependency on NVIDIA's volatility. Analyst sentiment has shifted to hold, reflecting diminished attractiveness amid lower option premiums.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
